MX2021008268A - Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. - Google Patents
Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.Info
- Publication number
- MX2021008268A MX2021008268A MX2021008268A MX2021008268A MX2021008268A MX 2021008268 A MX2021008268 A MX 2021008268A MX 2021008268 A MX2021008268 A MX 2021008268A MX 2021008268 A MX2021008268 A MX 2021008268A MX 2021008268 A MX2021008268 A MX 2021008268A
- Authority
- MX
- Mexico
- Prior art keywords
- cgrp
- treatment
- antibodies
- medication overuse
- overuse headache
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789828P | 2019-01-08 | 2019-01-08 | |
| US201962840967P | 2019-04-30 | 2019-04-30 | |
| US201962841585P | 2019-05-01 | 2019-05-01 | |
| US201962872983P | 2019-07-11 | 2019-07-11 | |
| PCT/US2020/012790 WO2020146535A1 (en) | 2019-01-08 | 2020-01-08 | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008268A true MX2021008268A (es) | 2021-08-05 |
Family
ID=71404208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008268A MX2021008268A (es) | 2019-01-08 | 2020-01-08 | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. |
Country Status (24)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3495392T (pt) | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| CN108014334B (zh) | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| EA033109B1 (ru) | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| GEAP202515803A (en) | 2019-05-02 | 2025-06-10 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| CN117813325A (zh) * | 2021-08-27 | 2024-04-02 | H.隆德贝克有限公司 | 使用抗cgrp抗体治疗丛集性头痛 |
| US20260125454A1 (en) * | 2022-08-11 | 2026-05-07 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cgrp antibody and use |
| CN118476508A (zh) * | 2024-06-27 | 2024-08-13 | 中国人民解放军总医院第一医学中心 | 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1644004A4 (en) * | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
| PT3495392T (pt) * | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| CN108014334B (zh) * | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| CN103585449B (zh) * | 2013-10-23 | 2016-06-22 | 高丽丽 | 用于治疗偏头痛的中药组合物 |
| CA2983030A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| SMT202600087T1 (it) * | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| CR20210373A (es) * | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
-
2020
- 2020-01-08 SG SG11202106878XA patent/SG11202106878XA/en unknown
- 2020-01-08 KR KR1020217023581A patent/KR20210114002A/ko not_active Ceased
- 2020-01-08 US US16/736,937 patent/US20200216525A1/en not_active Abandoned
- 2020-01-08 PE PE2021001141A patent/PE20211708A1/es unknown
- 2020-01-08 JP JP2021539682A patent/JP2022516957A/ja not_active Withdrawn
- 2020-01-08 TW TW109100630A patent/TW202030205A/zh unknown
- 2020-01-08 CA CA3123292A patent/CA3123292A1/en active Pending
- 2020-01-08 AU AU2020207299A patent/AU2020207299A1/en active Pending
- 2020-01-08 WO PCT/US2020/012790 patent/WO2020146535A1/en not_active Ceased
- 2020-01-08 BR BR112020018044-0A patent/BR112020018044A2/pt unknown
- 2020-01-08 MA MA054709A patent/MA54709A/fr unknown
- 2020-01-08 PH PH1/2021/551494A patent/PH12021551494A1/en unknown
- 2020-01-08 UA UAA202104194A patent/UA129265C2/uk unknown
- 2020-01-08 GE GEAP202515689A patent/GEAP202515689A/en unknown
- 2020-01-08 GE GEAP202015689A patent/GEP20257804B/en unknown
- 2020-01-08 JO JOP/2021/0166A patent/JOP20210166A1/ar unknown
- 2020-01-08 CN CN202411285298.5A patent/CN119303074A/zh active Pending
- 2020-01-08 EP EP20738512.1A patent/EP3908607A4/en active Pending
- 2020-01-08 CN CN202080007409.XA patent/CN113272324A/zh active Pending
- 2020-01-08 MX MX2021008268A patent/MX2021008268A/es unknown
-
2021
- 2021-06-30 CO CONC2021/0008665A patent/CO2021008665A2/es unknown
- 2021-07-07 IL IL284677A patent/IL284677A/en unknown
- 2021-07-07 DO DO2021000145A patent/DOP2021000145A/es unknown
- 2021-07-07 CL CL2021001813A patent/CL2021001813A1/es unknown
- 2021-07-07 NI NI202100063A patent/NI202100063A/es unknown
- 2021-07-14 EC ECSENADI202152193A patent/ECSP21052193A/es unknown
-
2023
- 2023-11-16 US US18/511,241 patent/US20240343784A1/en active Pending
-
2024
- 2024-11-08 JP JP2024195562A patent/JP2025032102A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000145A (es) | 2021-10-31 |
| NI202100063A (es) | 2021-12-01 |
| MA54709A (fr) | 2022-04-13 |
| AU2020207299A1 (en) | 2021-08-26 |
| JP2022516957A (ja) | 2022-03-03 |
| BR112020018044A2 (pt) | 2021-08-10 |
| US20240343784A1 (en) | 2024-10-17 |
| PE20211708A1 (es) | 2021-09-01 |
| GEP20257804B (en) | 2025-10-10 |
| ECSP21052193A (es) | 2021-08-31 |
| CL2021001813A1 (es) | 2021-12-24 |
| EP3908607A1 (en) | 2021-11-17 |
| KR20210114002A (ko) | 2021-09-17 |
| EP3908607A4 (en) | 2022-10-05 |
| WO2020146535A1 (en) | 2020-07-16 |
| JOP20210166A1 (ar) | 2023-01-30 |
| CA3123292A1 (en) | 2020-07-16 |
| CN113272324A (zh) | 2021-08-17 |
| CN119303074A (zh) | 2025-01-14 |
| TW202030205A (zh) | 2020-08-16 |
| CO2021008665A2 (es) | 2021-07-19 |
| GEAP202515689A (en) | 2025-04-25 |
| UA129265C2 (uk) | 2025-03-05 |
| SG11202106878XA (en) | 2021-07-29 |
| PH12021551494A1 (en) | 2023-05-08 |
| JP2025032102A (ja) | 2025-03-11 |
| US20200216525A1 (en) | 2020-07-09 |
| IL284677A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| MX2021008267A (es) | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
| CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
| CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
| MX2024006565A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
| ECSP20063690A (es) | Anticuerpos | |
| MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| CO2019011640A2 (es) | Métodos y composiciones para la reducción de la inmunogenicidad | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| CL2023001140A1 (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| MX2017004196A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. | |
| BR112019011461A2 (pt) | terapia celular à base de nk melhorada | |
| MX2023015070A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. | |
| MX2021012848A (es) | Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. |